Achieve Life Sciences Inc (ACHV) Stock Price, Quote & News

Company Profile

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washing...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 210 2217

Website: www.achievelifesciences.com

Address:

22722 29th Dr. SE, Suite 100, Bothell, United States

leshgo Dec. 4 at 7:24 PM

$ACHV Just hold. real easy game. All I need is patience💬

0 · Reply

Sieppo Dec. 4 at 6:54 PM

$ACHV and still! You have to be some kind of a special idiot to short this or see the movement as anything bearish. June is quickly approaching!

0 · Reply

Limpi Dec. 4 at 5:46 PM

$ACHV Bullish

0 · Reply

DistributionEquity Dec. 4 at 5:31 PM

This is very relevant to my other favorite pharma $RVPH, but it shows how good a position $ACHV may be in to commercialize not just smoking cessation but also vaping https://www.statnews.com/2025/12/04/fda-considers-single-clinical-trial-for-new-product-approvals/

0 · Reply

QuantumLoop7 Dec. 4 at 3:18 PM

$ACHV I like thinking about free float here too insiders sit on ~80%+ of the shares which leaves maybe ~40M shares for the market so when Next NRG puts out a real catalyst and daily volume jumps from ~2M to 5M+ it doesn’t take much new demand to move price hard

1 · Reply

Markstockguy Dec. 4 at 3:16 PM

$XXII $ACHV $MO $TPB $CHUC's mission is to provide adult smokers with better alternatives to cigarettes. The Company is profitable, growing rapidly, and headed for 25-40X return from today's market price. Charles A. Gardner, PhD Tobacco Harm Reduction Expert "Can we please just stop the "vaping is a gateway to smoking" myth? All over the world (in countries that allow nicotine vapes), the age group with the steepest rate of smoking decline is young adults. No "gateway." The irony of that myth is that it is actually an admission that the person making that claim KNOWS nicotine vapes are SAFER. Otherwise, why care?" https://media.licdn.com/dms/image/v2/D4E22AQG9Bl38yjnYqg/feedshare-shrink_800/B4EZrlrzoCKoAo-/0/1764790057790?e=1766620800&v=beta&t=qMjcm2UYdresg2WJUOAdRtJ2VGDAnCXM73N1Dn2ndE4

1 · Reply

MiguelitoLoveless Dec. 4 at 3:12 PM

$ACHV interesting strength today with no apparent catalyst

1 · Reply

justiceforb_85 Dec. 4 at 2:27 AM

$ACHV company with very little cash. Are they planning a raise soon?

1 · Reply

TheRardFather Dec. 4 at 12:38 AM

$ACHV I slept on this one I reallly need them to do a capital raise so I can get it at $3.50 again

3 · Reply

Uphillskier Dec. 3 at 11:55 PM

$ACHV who will be selling to these shorts? Not me. Happy to take their $ for borrowing my shares, though. Tick tock 🍋⏰

2 · Reply

Achieve Life Sciences, Inc. (ACHV) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:00 AM EST - 4 weeks ago

Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

Nov 3, 2025, 8:30 AM EST - 4 weeks ago

Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation

Oct 29, 2025, 8:30 AM EDT - 5 weeks ago

Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025

Oct 20, 2025, 8:30 AM EDT - 6 weeks ago

Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer

Oct 20, 2025, 7:15 AM EDT - 6 weeks ago

Achieve: Expedited Review Of Cytisinicline Sets The Stage For Development Expansion

Oct 17, 2025, 7:30 AM EDT - 6 weeks ago

Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation

Oct 2, 2025, 4:01 PM EDT - 2 months ago

Achieve Life Sciences Announces Granting of New Hire Inducement Awards

Sep 22, 2025, 8:30 AM EDT - 2 months ago

Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline's Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD

Sep 18, 2025, 8:30 AM EDT - 2 months ago

Achieve Life Sciences Promotes Craig Donnelly to Chief Operations Officer

Sep 11, 2025, 5:01 PM EDT - 2 months ago

Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer

Sep 3, 2025, 8:30 AM EDT - 3 months ago

Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation

Sep 2, 2025, 8:30 AM EDT - 3 months ago

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

Aug 21, 2025, 2:11 PM EDT - 3 months ago

Achieve Life Sciences Inches Closer To FDA Nod For First New Quit-Smoking Drug In 20 Years

Aug 8, 2025, 10:12 AM EDT - 4 months ago

Achieve Life Sciences, Inc. (ACHV) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 11:25 AM EDT - 4 months ago

Achieve (ACHV) Q2 Net Loss Hits $12.7M

Aug 7, 2025, 7:30 AM EDT - 4 months ago

Achieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

Jul 29, 2025, 8:30 AM EDT - 4 months ago

Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference

Jul 24, 2025, 8:30 AM EDT - 4 months ago

Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 7, 2025

Jul 7, 2025, 1:55 PM EDT - 5 months ago

Achieve Life Sciences: Nearing Commercialization Of A Best-In-Class Pharmaceutical Product For Smoking Cessation

Jun 30, 2025, 7:52 PM EDT - 5 months ago

Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters' Option to Purchase Additional Securities

Jun 26, 2025, 11:43 PM EDT - 5 months ago

Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering

Jun 26, 2025, 4:03 PM EDT - 5 months ago

Achieve Life Sciences Announces Proposed Underwritten Public Offering

Jun 26, 2025, 4:02 PM EDT - 5 months ago

Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades

OMC

Jun 3, 2025, 6:28 PM EDT - 6 months ago

Achieve Life Sciences: FDA Approval Not Assured, But Valuation Justifies Risk

May 28, 2025, 8:30 AM EDT - 6 months ago

Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 8:30 AM EDT - 7 months ago

Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake

May 13, 2025, 12:16 PM EDT - 7 months ago

Achieve Life Sciences, Inc. (ACHV) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:30 AM EDT - 7 months ago

Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program

May 6, 2025, 8:30 AM EDT - 7 months ago

Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025

Apr 21, 2025, 11:19 AM EDT - 8 months ago

Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine

Mar 11, 2025, 2:52 PM EDT - 9 months ago

Achieve Life Sciences, Inc. (ACHV) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 7:30 AM EDT - 9 months ago

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program

Mar 7, 2025, 8:30 AM EST - 9 months ago

Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference

Mar 6, 2025, 8:30 AM EST - 9 months ago

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025

Feb 11, 2025, 8:30 AM EST - 10 months ago

Achieve Life Sciences to Present at the Oppenheimer Healthcare Life Sciences Conference

Feb 10, 2025, 8:30 AM EST - 10 months ago

Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial

Jan 10, 2025, 8:30 AM EST - 11 months ago

Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors

Jan 7, 2025, 8:30 AM EST - 11 months ago

Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission

Jan 6, 2025, 8:30 AM EST - 11 months ago

Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

Dec 9, 2024, 8:30 AM EST - 1 year ago

Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer

Dec 3, 2024, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA

Nov 25, 2024, 7:54 AM EST - 1 year ago

Smoking Cessation Pipeline Insight 2024, with Focus on Emerging Drugs Cytisinicline (Achieve Life Sciences), EMB-001(Embera Pharmaceuticals) and SBP-9330 (Camino Pharma)

Nov 9, 2024, 7:32 AM EST - 1 year ago

Achieve Life Sciences, Inc. (ACHV) Q3 2024 Earnings Call Transcript

Oct 23, 2024, 8:00 AM EDT - 1 year ago

Achieve Life Sciences President and CMO, Dr. Cindy Jacobs, Speaks at FDA and NIH Smoking Cessation Public Meeting

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline

Oct 1, 2024, 8:45 AM EDT - 1 year ago

Achieve Life Sciences Strengthens Leadership with Appointment of Dr. Mark Rubinstein, Nicotine Dependence Expert, as New Head of Medical Affairs

Aug 26, 2024, 4:30 PM EDT - 1 year ago

Achieve Life Sciences Announces Changes in Executive Leadership and Board of Directors

Aug 14, 2024, 4:58 AM EDT - 1 year ago

Achieve Life Sciences, Inc. (ACHV) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 4:01 PM EDT - 1 year ago

Achieve Life Sciences Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

leshgo Dec. 4 at 7:24 PM

$ACHV Just hold. real easy game. All I need is patience💬

0 · Reply

Sieppo Dec. 4 at 6:54 PM

$ACHV and still! You have to be some kind of a special idiot to short this or see the movement as anything bearish. June is quickly approaching!

0 · Reply

Limpi Dec. 4 at 5:46 PM

$ACHV Bullish

0 · Reply

DistributionEquity Dec. 4 at 5:31 PM

0 · Reply

QuantumLoop7 Dec. 4 at 3:18 PM

1 · Reply

Markstockguy Dec. 4 at 3:16 PM

1 · Reply

MiguelitoLoveless Dec. 4 at 3:12 PM

$ACHV interesting strength today with no apparent catalyst

1 · Reply

justiceforb_85 Dec. 4 at 2:27 AM

$ACHV company with very little cash. Are they planning a raise soon?

1 · Reply

TheRardFather Dec. 4 at 12:38 AM

$ACHV I slept on this one I reallly need them to do a capital raise so I can get it at $3.50 again

3 · Reply

Uphillskier Dec. 3 at 11:55 PM

$ACHV who will be selling to these shorts? Not me. Happy to take their $ for borrowing my shares, though. Tick tock 🍋⏰

2 · Reply

They_Call_Me_Tater_Salad Dec. 3 at 9:05 PM

$ACHV That's exactly why I don't day trade... You think it'll go up and it goes down... You think it'll go down and it goes up. You wait for it "to get back into the $3's" and you miss an entry at $4 that never repeats... It's a game that almost everybody loses, and I'm not that 1 in 1,000 person who can win at that game long term.

6 · Reply

Sieppo Dec. 3 at 3:21 PM

$ACHV I guess shorts are already out of powder 😂.. I'd like this to settle firmly above 5 for now, the sky is pretty much open to 10ish after that.

1 · Reply

Deeconomics Dec. 3 at 11:48 AM

$ACHV https://share.google/6oc2bWO2Va7ekW5qI

0 · Reply

TheRardFather Dec. 3 at 9:42 AM

$ACHV When do you think they’ll do their capital raise?

1 · Reply

Shane779453 Dec. 3 at 1:11 AM

$ACHV Saw today Franklin Resources now owns almost 13%

1 · Reply

AB5HUNNID Dec. 3 at 1:03 AM

$ACHV

0 · Reply

They_Call_Me_Tater_Salad Dec. 1 at 7:22 PM

$ACHV Shorts are definitely at it again...

2 · Reply

Drashkawisha Dec. 1 at 12:28 PM

$ACHV The clinical case is solid and the June 2026 PDUFA is a clear target. However, launching a mass-market drug requires serious capital. For the long-term holders here: Is the consensus that they will seek a Big Pharma partnership to fund the launch, or are we modeling a capital raise in H1 2026 to bridge the gap? Trying to plan my position size. Thanks

2 · Reply

Deeconomics Dec. 1 at 11:56 AM

$ACHV It will be financial suicide for smokers not to enroll in a smoking cessation program in 2026: AI Overview - Health insurance premiums are expected to rise significantly in 2026, with Affordable Care Act (ACA) Marketplace plans projected to increase by about 26% on average nationally. Compounded Increases for Smokers. Under the ACA, insurers in many states can charge a tobacco surcharge of up to 50% of the total premium. If basic premiums rise by 26% and the surcharge is 50%, the total cost increase for a smoker could be substantial, creating a significant financial burden. Potential Need for Cytisinicline Insurers that apply surcharges are mandated under the ACA to remove the surcharge if an individual enrolls in a smoking cessation program. significant and compounding premium increases for smokers absolutely create a greater financial incentive and potential need for effective smoking cessation treatments. If approved by the FDA in 2026, cytisinicline could be a blockbuster.

3 · Reply

Drashkawisha Dec. 1 at 10:37 AM

$ACHV With ~$48M in cash and a ~$14M quarterly burn, the runway ends exactly at the PDUFA date (June 2026). You can't launch a drug with $0 in the bank. The real question: Are we expecting a massive dilution event before the NDA submission to clear the runway, or are you betting on a buyout saving us? The timing here is tricky.

2 · Reply

leshgo Dec. 1 at 5:28 AM

$ACHV ACHV wouldn't be strange to reach $10 before the end of 2025.

1 · Reply

leshgo Dec. 1 at 12:26 AM

$ACHV Thanks to Mr. Tater, I have faith in ACHV. LFG🚀🚀

1 · Reply

Market Cap	242.22M
Revenue (ttm)	0.00
Net Income (ttm)	-39.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.04

Volume	720,439
Avg Vol	1,347,792
Day's Range	N/A - N/A
Shares Out	53.23M
Stochastic %K	91%
Beta	1.69
Analysts	Strong Sell
Price Target	$16.71